# Biomarker-driven Targeted Therapy in Patients With Recurrent Platinum-resistant Epithelial Ovarian Cancer

> **NCT05044871** · PHASE2 · COMPLETED · sponsor: **Tongji Hospital** · enrollment: 108 (actual)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** Pamiparib
- **DRUG:** Bevacizumab
- **DRUG:** Tislelizumab
- **DRUG:** Nab paclitaxel
- **DRUG:** Bevacizumab + Nab paclitaxel (intense dose-dense)

## Key facts

- **NCT ID:** NCT05044871
- **Lead sponsor:** Tongji Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-07-22
- **Primary completion:** 2025-02-17
- **Final completion:** 2025-02-17
- **Target enrollment:** 108 (ACTUAL)
- **Last updated:** 2025-06-08

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05044871

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05044871, "Biomarker-driven Targeted Therapy in Patients With Recurrent Platinum-resistant Epithelial Ovarian Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05044871. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*